Recent Articles

Corporate Culture of Health: Elusive and Expensive
David B. Nash, MD, MBA
February 2020 Vol 13, No 1 - Editorial
Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization
Allison Petrilla, MPH, Elizabeth Marrett, MPH, Xian Shen, PhD, MS, BS, Winghan Jacqueline Kwong, PharmD, PhD, Edmund Pezalla, MD, MPH
February 2020 Vol 13, No 1 - Business, Original Research
Stakeholder Perspective
Abuse-Deterrent Formulations of Prescription Opioids: A Missed Opportunity to Address the Current Opioid Crisis?
by Atheer Kaddis, PharmD
Medication Use Before and After Hospitalization for Chronic Obstructive Pulmonary Disease in a Cohort of Elderly Patients with a Medicare Advantage Plan
Qingqing Xu, MS, Sarah S. Laxa, PharmD, Omar Serna, PharmD, BCACP, Sujit S. Sansgiry, MS, PhD
February 2020 Vol 13, No 1 - Clinical, Original Research
Stakeholder Perspective
Improving Medication Use for Chronic Diseases by Reducing Costs, Increasing Patient Adherence
by F. Randy Vogenberg, PhD

Most Popular Articles

Outcomes-Based Contracting for Disease-Modifying Therapies in Multiple Sclerosis: Necessary Conditions for Paradigm Adoption
Cori Gray, PharmD, James T. Kenney, RPh, MBA
December 2019 Vol 12, No 8 - Business, Original Article
The Business Case for Social Determinants
David B. Nash, MD, MBA
December 2019 Vol 12, No 8 - Editorial
Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis
Rajeshwari Punekar, MPH, PhD, Jeannie Choi, PharmD, Susan H. Boklage, MS, MPH, Melitza Iglesias-Rodriguez, MD, Kamala Nola, PharmD, MS
December 2019 Vol 12, No 8 - Clinical, Original Research
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
David Campbell, PharmD, MS, Marlo Blazer, PharmD, BCOP, Lisa Bloudek, PharmD, MS, John Brokars, MS, Dinara Makenbaeva, MD, MBA
November 2019 Vol 12, No 7 - Business, Business, Original Research, Original Research
The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population
Nihar R Desai, MD, MPH, Pamala Reed, DrPH, MPH, Paula J Alvarez, RPh, MBA, MPH, Jeanene Fogli, PhD, RD, Steven D Woods, PharmD, Mary Kay Owens, RPh, CPh
November 2019 Vol 12, No 7 - Business, Original Research

Select Drug Profiles

Balversa (Erdafitinib), First-in-Class FGFR Kinase Inhibitor, Approved for Patients with Metastatic Urothelial Carcinoma and FGFR Mutations
Loretta Fala
Cablivi (Caplacizumab-yhdp): First Targeted, Nanobody-Based Therapy Approved for Adults with Acquired Thrombotic Thrombocytopenic Purpura
Loretta Fala

Reader Poll

*Should the government fund healthcare cost-sharing payments to insurers to reduce the economic burden on consumers?


  • Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME